Gossamer Bio, Inc.: Diferență între versiuni
Admin (discuție | contribuții) (Pagină nouă: Pagina dedicata companiei Gossamer Bio, Inc. listata cu simbolul US.GOSS ==Descriere companie== Gossamer Bio, Inc. (www.gossamerbio.com) is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. The Company has six programs: three clinical-stage product candidates and three preclinical programs. Its pipeline includes GB001, GB002, GB004, GB1275, A...) |
(The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).) |
||
| Linia 1: | Linia 1: | ||
Pagina dedicata companiei Gossamer Bio, Inc. listata cu simbolul US.GOSS | Pagina dedicata companiei Gossamer [[BIO|Bio]], Inc. listata cu simbolul US.GOSS | ||
==Descriere companie== | ==Descriere companie== | ||
Versiunea curentă din 26 noiembrie 2024 04:53
Pagina dedicata companiei Gossamer Bio, Inc. listata cu simbolul US.GOSS
Descriere companie[edit | ]
Gossamer Bio, Inc. (www.gossamerbio.com) is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. The Company has six programs: three clinical-stage product candidates and three preclinical programs. Its pipeline includes GB001, GB002, GB004, GB1275, Autoimmune program and Oncology program. GB001 is an oral antagonist of prostaglandin D2 receptor 2, or DP2, is being developed for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. GB002 is an orally inhaled, small molecule, selective platelet-derived growth factor, or PDGF, receptor kinase inhibitor is being developed for the treatment of pulmonary arterial hypertension. GB004 is being developed for Inflammatory Bowel Disease (IBD). GB1275 is a CD11b agonist.
Grafic actiuni companie[edit | ]